example 2 [WO2013026797A1]   Click here for help

GtoPdb Ligand ID: 12114

Compound class: Synthetic organic
Comment: This is one of the compounds that are claimed as PDE4B inhibitors in Boehringer Ingelheim's patent WO2013026797A1 [2]. The compounds are claimed for potential to treat inflammatory or allergic diseases of the respiratory tract, such as COPD or asthma. Boehringer Ingelheim's oral PED4B clinical lead BI 1015550 has entered clinical studies [1,3], but as no structure has been disclosed, it is not clear if BI 1015550 is one of the examples in WO2013026797A1.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 123.34
Molecular weight 448.14
XLogP 0.59
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OCC1(CCC1)Nc1nc(nc2c1S(=O)CC2)N1CCC(CC1)c1ncc(cn1)Cl
Isomeric SMILES OCC1(CCC1)Nc1nc(nc2c1S(=O)CC2)N1CCC(CC1)c1ncc(Cl)cn1
InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)
InChI Key UHYCLWAANUGUMN-UHFFFAOYSA-N
References
1. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. (2022)
BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.
Front Pharmacol, 13: 838449. [PMID:35517783]
2. Pouzet PAJ, Nickoluas P, Werthmann U, Frutos RP, Yang BS, Kim S, Mulder JA, Patel N, Senanayake CH, Tampone TG et al.. (2013)
Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma.
Patent number: WO2013026797A1. Assignee: Boehringer Ingelheim International Gmbh. Priority date: 24/08/2011. Publication date: 28/02/2013.
3. Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM et al.. (2022)
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
N Engl J Med, 386 (23): 2178-2187. [PMID:35569036]